Sermorelin Research: GHRH Analogue Studies and Half-Life Considerations

Research Notice: All peptides sold by The Peptide Store are intended for laboratory research purposes only. They are not for human consumption, not approved by the FDA, and not intended to diagnose, treat, cure, or prevent any disease.

Research summary: Sermorelin (GRF 1-29 NH2) is the first 29 amino acids of Growth Hormone Releasing Hormone (GHRH) and the biologically active fragment of the 44-amino-acid parent molecule. It binds the GHRH receptor to stimulate pituitary GH release through a physiological upstream mechanism, and has a plasma half-life of roughly 10–20 minutes. Marketed as Geref, it received FDA approval for a diagnostic indication. Sold for laboratory research use only.

Sermorelin (GRF 1-29 NH2) comprises the first 29 amino acids of endogenous Growth Hormone Releasing Hormone (GHRH) and represents the biologically active fragment of the 44-amino acid parent molecule. It received FDA approval for a diagnostic indication, providing a clinical data foundation unusual among research peptides.

GHRH and the Hypothalamic-Pituitary Axis

GHRH is produced in the hypothalamus and acts on somatotroph cells in the anterior pituitary to stimulate GH synthesis and pulsatile release. Sermorelin binds the same GHRH receptor (GHRHR), eliciting GH release through a physiological upstream mechanism rather than direct GH administration.

FDA Approval and Clinical Data

Sermorelin (marketed as Geref) received FDA approval for diagnostic assessment of pituitary GH production capacity. The clinical trials conducted during its development established its pharmacokinetic profile, receptor binding characteristics, and safety data in human subjects — an unusually solid data foundation for a research peptide.

Half-Life and Research Protocol Design

Sermorelin has a plasma half-life of approximately 10–20 minutes, similar to endogenous GHRH. This short half-life has been a key consideration in research protocol design. The relatively brief action window has driven interest in modified analogues with extended stability (such as CJC-1295), though Sermorelin remains widely used for its more physiologically native pulse kinetics.

Synergy With GHS-R Agonists

Research comparing GHRH analogues (like Sermorelin) to ghrelin mimetics (like Ipamorelin) has consistently shown synergistic GH secretion when both receptor types are engaged simultaneously. This complementary mechanism underlies the common research design pairing GHRH analogues with GHS-R agonists.